Yumanity Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Yumanity Therapeutics Inc. (NASDAQ:YMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases caused by protein misfolding, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The company's lead product candidate is YTX-7739, a novel small-molecule inhibitor of stearoyl-CoA desaturase in Phase I clinical trials for Parkinson's disease and related alpha-synuclein disorders; it is also advancing YTX-9184 in preclinical studies for neurological disorders. Yumanity maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. for programs targeting amyotrophic lateral sclerosis and frontotemporal lobar dementia. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates primarily in the United States with approximately 40 employees. In June 2022, Yumanity announced definitive agreements to sell its lead clinical-stage neurology asset to Janssen Pharmaceutica and to merge with Kineta Inc., a clinical-stage immuno-oncology company, in a reverse merger transaction; the merger completed in December 2022, with the combined entity operating as Kineta Inc. (NASDAQ:KA) and Yumanity's stockholders receiving approximately 15% ownership. Prior strategic moves include a 2020 reverse merger with Proteostasis Therapeutics to access public markets and support pipeline advancement.
Why Are Chinese Stocks Up Today?
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
Best Penny Stocks to Buy That Exploded Today? 3 to Watch
Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?
Yumanity Therapeutics Shares Trading Higher Today - Read Here Why
Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience Conference
Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
Yumanity Therapeutics' Glioblastoma Candidate Shows Efficacy In Animal Studies
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021
Yumanity Therapeutics Provides Update on Its Lead Parkinson's Disease Clinical Program, YTX-7739
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference